natgillin/translations-raw huggingface dataset:
allowing the yeast to convert at least 50% of the water soluble glucose and less than 20% of the water soluble xylose of the first conversion medium to a first propagated yeast and a first portion of the fermentation product in a first conversion step conducted for a first conversion time and having a first sugar-to-cells conversion ratio in a range of from 5% to 25%, wherein the first sugar-to-cells conversion ratio is a percent weight ratio of the glucose and xylose converted to the propagated yeast in the first conversion step to the water soluble glucose and xylose totally converted in the first conversion medium, on a carbon basis; 
puštanja da kvasac pretvara najmanje 50% u vodi topljive glukoze i manje od 20% u vodi topljive ksiloze iz prvog pretvorbenog medija u prvi trazmnoženi kvasac i prvi dio produkta vrenja u prvom koraku pretvorbe kojeg se provodi tijekom prve pretvorbe i ima prvi pretvorbeni omjer između šećera i stanica u rasponu od 5% do 25%, gdje je prvi pretvorbeni omjer između šećera i stanica postotni težinski omjer između glukoze i ksiloze pretvorene u trazmnoženi kvasac u prvom koraku pretvorbe i posve pretvorene u vodi topljive glukoze i ksiloze u prvom pretvorbenom mediju, na bazi ugljika;
allowing the yeast to convert at least a portion of the water soluble glucose and xylose in the second conversion medium to at least a second propagated yeast and a second portion of the fermentation product in a second conversion step conducted for a second time which is greater than the first conversion time and having a second sugar-to-cells conversion ratio which is less than the first sugar-to-cells conversion ratio, wherein the second sugar-to-cells conversion ratio is a percent weight ratio of the water soluble glucose and xylose converted to the propagated yeast in the second conversion step to totally converted water soluble glucose and xylose in the second conversion medium, on a carbon basis. 
puštanja da kvasac pretvara u najmanju ruku dio u vodi topljive glukoze i ksiloze u drugom pretvorbenom mediju u najmanju ruku drugi trazmnoženi kvasac i drugi dio produkta vrenja u drugom koraku pretvorbe kojeg se provodi u drugom vremenu koje je dulje od vremena prve pretvorbe i ima drugi pretvorbeni omjer između šećera i stanica koji je manji od prvog pretvorbenog omjera između šećera i stanica, gdje je drugi pretvorbeni omjer između šećera i stanica postotni težinski omjer u vodi topljive glukoze i ksiloze pretvorene u trazmnoženi kvasac u drugom koraku pretvorbe i posve pretvorene u vodi topljive glukoze i ksiloze u drugom pretvorbenom mediju, na bazi ugljika.
The process of any of claims 1 to 2, wherein the first conversion step is conducted for a first conversion time which is less than 30 hours.. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se prvi korak pretvorbe provodi u vremenu prve pretvorbe koje je manje od 30 sati.
The process of any of claims 1 to 6, wherein the second conversion step is conducted for a second conversion time which is less than 72 hours.. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se drugi korak pretvorbe provodi u vremenu druge pretvorbe koje je manje od 72 sata.
The process of any of claims 1 to 10, wherein the first conversion medium and the second conversion medium have a dry matter content which is less than 30% and greater than 5%.. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što prvi pretvorbeni medij i drugi pretvorbeni medij imaju sadržaj suhe tvari manji od 30% i veći od 5%.
The process of any of claims 1 to 17, wherein the first conversion step and the second conversion step are conducted in separated vessels. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što se prvi korak pretvorbe i drugi korak pretvorbe provodi u odvojenim posudama.
A process for synthesizing hydrocarbons, comprising the steps of: formulating a hydrogen-lean syngas stream in a non-catalytic partial oxidation reaction; 
Postupak sinteze ugljikovodika, naznačen time što se sastoji u koracima: formuliranja struje sinteznog plina siromašne vodikom reakcijom nekatalitičke djelomične oksidacije;
recycling at least a portion of said naphtha to a hydrogen generator to form a hydrogen rich syngas stream, wherein said hydrogen generator comprises a steam methane reformer (44), an autothermal reformer (60) or a combination thereof; and 
recikliranja u najmanju ruku dijela navedene nafte u generator vodika kako bi se dobilo struju sinteznog plina bogatu vodikom, gdje navedeni generator vodika sadrži parni metanski reformer (44), autotermalni reformer (60) ili njihovu kombinaciju; i
combining said hydrogen-rich syngas stream with the hydrogen-lean syngas stream and feeding the combined syngas stream to the Fischer-Tropsch reaction to enhance synthesis of hydrocarbons. 
kombiniranja navedene struje sinteznog plina bogate vodikom sa strujom sinteznog plina siromašnom vodikom i dodavanjem kombinirane struje sinteznog plina u Fischer-Tropschovu reakciju kako bi se poboljšalo sintezu ugljikovodika.
The process according to claim 2, wherein said thermal gasifier gasifies a member selected from the group consisting of coal, biomass, petroleum resids, petcoke, municipal waste, plastics, wood waste, demetallized tire scrap, forestry waste material, waste water biomass, sewage biomass, agricultural waste, agricultural byproducts, carbonaceous material and mixtures thereof. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što navedeni toplinski rasplinjač rasplinjava člana kojeg se bira iz skupine koju čine ugljen, biomasa, naftni ostaci, naftni koks, komunalni otpad, plastika, drvni otpad, demetalizirani ostaci autoguma, šumarski otpadni materijal, biomasa iz otpadne vode, biomasa iz kanalizacije, poljoprivredni otpad, poljoprivredni nusproizvodi, ugljični materijal i njihove smjese.
recycling at least a portion of said fuel gas to a second hydrogen generator, which is an autothermal reformer (ATR), to form a supplemental syngas stream; and (f) combining said supplemental syngas stream with the hydrogen lean stream. 
recikliranja u najmanju ruku dijela navedenog plinovitog goriva u drugi generator vodika, koji je autotermalni reformer (ATR), kako bi se dobilo dodatnu struju sinteznog plina; i kombiniranja navedene dodatne struje sinteznog plina sa strujom siromašnom vodikom.
A composition comprising a mixture of drug conjugate compounds according to any one of claims 2 to 8, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 1 to about 8. 
Sastav, naznačen time, da obuhvaća mješavinu spojeva lijeka i konjugata u skladu s bilo kojim od zahtjeva 2 do 8, pri čemu prosječna opterećenost lijekom po protutijelu u mješavini spojeva konjugata protutijelo-lijek, iznosi od oko 1 do oko 8.
The conjugate or composition for use according to claim 11, wherein the disease is cancer. 
Konjugat ili sastav za uporabu prema zahtjevu 11, naznačen time, da bolest je rak.
A pharmaceutical composition comprising the conjugate according to any one of claims 2 to 7 or the composition according to claim 8, and a pharmaceutically acceptable diluent, carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća konjugat u skladu s bilo kojim od zahtjeva 2 do 8, ili sastav u skladu sa zahtjevom 9, te farmaceutski prikladan razrjeđivač, nosač ili pomoćno sredstvo.
A compound of formula II: wherein: 
Spoj, naznačen time, da ima formulu II:
The compound of claim 1, wherein one R3b group is F and the remaining R3b groups are H. 
Spoj prema patentnom zahtjevu 1, naznačen time, da skupina R3b je F, a preostale skupine R3b su H.
A pharmaceutical composition, comprising a compound of Formula II as described in any one of claims 1-22 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da obuhvaća spoj formule II u skladu s bilo kojim patentnim zahtjevom od 1 do 22 ili njegovu farmaceutski prihvatljivu sol te farmaceutski prihvatljivi nosač, otapalo ili ekscipijens.
A compound of Formula II as described in any one of claims 1-22 or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis of a disease or condition mediated by TRPA1 activity. 
Spoj formule II u skladu s bilo kojim patentnim zahtjevom od 1 do 22 ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da je za primjenu u liječenju ili profilaksi oboljenja ili stanja posredovanog aktivnošću TRPA1.
The compound for use of claim 27 wherein the disease or condition is pain, itch, an inflammatory disorder, an inner ear disorder, fever or another disorder of thermoregulation, tracheobronchial or diaphragmatic dysfunction, a gastrointestinal or urinary tract disorder, chronic obstructive pulmonary disease, incontinence, or a disorder associated with reduced blood flow to the CNS or CNS hypoxia, in particular pain, arthritis, itch, cough, asthma, inflammatory bowel disease, or an inner ear disorder. 
Spoj za primjenu prema patentnom zahtjevu 27, naznačen time, da je oboljenje ili stanje bol, svrab, upalni poremećaj, poremećaj unutarnjeg uha, vrućica ili neki drugi poremećaj termoregulacije, traheobronhijalna disfunkcija ili disfunkcija dijafragme, gastrointestinalni poremećaj ili poremećaj mokraćnog sustava, kronična opstruktivna bolest pluća, inkontinencija ili poremećaj povezan sa smanjenim dotokom krvi u SŽS ili hipoksija SŽS-a, a posebice bol, artritis, svrab, kašalj, astma, upalna bolest crijeva ili poremećaj unutarnjeg uha.
determination of target values for the optimum compression distance in the shoulder, waist and hip zones indicating how far said mattress (1) has to be compressed in the shoulder, waist and hip zones, so that the spine of the person lying sideways on the mattress has the same shape as standing in the upright position; 
određivanje ciljnih vrijednosti za optimalnu kompresijsku udaljenost u zonama ramena, struka i kuka koje ukazuju na to koliko madrac (1) mora biti stisnut u zonama ramena, struka i kuka, tako da kralježnica osobe koja leži bočno na madracu ima isti oblik kao kad stoji u uspravnom položaju;
selection of inserts (3, 4, 5) to be used from a list or stock of possible inserts (3, 4, 5), which in combination with the base part (2) have the desired deformation characteristics at these positions and when this person is lying sideways on the mattress (1), the degree of compression in the shoulder, waist and hip zones is equal to said target values; 
odabir umetaka (3, 4, 5) koji će se koristiti s popisa ili zalihe mogućih umetaka (3, 4, 5), koji u kombinaciji s osnovnim dijelom (2) imaju željene deformacijske karakteristike na tim položajima i kad ta osoba leži bočno na madracu (1), stupanj kompresije u zonama ramena, struka i kukova jednak je navedenim ciljnim vrijednostima;
Method according to claim 1, characterised in that the shape of the side and back outlines of the body of the person is determined in a standing position of the body. 
Metoda prema zahtjevu 1, naznačena time što se oblik bočnih i stražnjih obrisa tijela osobe određuje u stojećem položaju tijela.
Method according to claim 3, characterised in that the shape of the side and back outlines of the body of the person is determined by rolling rollers (13) over the side and back of the body, whereby the rollers are connected to a system (11) that can measure the horizontal displacement of the rollers (13). 
Metoda prema zahtjevu 2, naznačena time što se oblik bočnih i stražnjih obrisa tijela osobe određuje valjanjem valjaka (13) preko bočne i stražnje strane tijela, pri čemu su valjci spojeni na sustav (11) koji može mjeriti vodoravni pomak valjka (13).
Method according to claim 4, characterised in that on the basis of the known deformation characteristics of the base part (2) and the known deformation characteristics of inserts (3,4,5), the material from which the inserts (3,4,5) have to be selected can be calculated by a computer model in order to make a mattress for a person, such that when this person is lying sideways on the mattress, the degree of compression in the shoulder, waist and hip zones is equal to the target values. 
Metoda prema zahtjevu 4, naznačena time što na temelju poznatih deformacijskih karakteristika osnovnog dijela (2) i poznatih deformacijskih karakteristika umetaka (3,4,5), materijal od kojeg umeci (3,4,5) mogu biti izabrani može se izračunati pomoću računalnog modela kako bi se napravio madrac za osobu, takav da je stupanj kompresije u zonama ramena, struka i kukova jednak ciljnim vrijednostima, kad ta osoba leži bočno na madracu.
Method according to any of the previous claims, characterised in that the width (B3, B4, B5) of the inserts (3,4,5) is adapted to the height of the person. 
Metoda prema bilo kojem od prethodnih zahtjeva, naznačena time da je širina (B3, B4, B5) umetaka (3,4,5) prilagođena visini osobe.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the LSD is chosen from a primary lysosomal hydrolase defect, a post-translational processing defect of lysosomal enzymes, a trafficking defect for lysosomal enzymes, a defect in lysosomal enzyme protection, a defect in soluble non-enzymatic lysosomal proteins, a transmembrane (non-enzyme) protein defect, and an unclassified defect. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, pri čemu je LSD odabran od primarnog defekta lizosomskih hidrolaza, posttranslacijskog defekta procesiranja lizosomskih enzima, defekta prijenosa za lizosomske enzime, defekta u zaštiti lizosomskih enzima, defekta u topljivim ne-enzimatskim lizosomskim proteinima, defekta transmembranskih (ne-enzimskih) proteina i neklasificiranog defekta.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the LSD is chosen from Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, pri čemu je LSD odabran od Tay-Sachsove bolesti, AB varijante Tay-Sachsove bolesti, Sandhoffove bolesti, Niemann-Pick bolesti tipa A, Niemann-Pick bolesti tipa B, Fabryjeve bolesti, neuronske ceroidne lipofuscinoze, Krabbove bolest, Farberove bolesti, Gaucherove bolesti, metakromatske leukodistrofije, multiple deficijencije sulfataze, mukolipidoze II, mukolipidoze III, MPS III, MPS VII, GM1 gangliozidoze i aspartilglukozaminurije.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 to reverse progression of a LSD or one or more symptoms associated with a LSD over time, wherein the use comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1 kako bi se unazadila progresija LSD-a ili jednog ili više simptoma povezanih s LSD-jem tijekom vremena, pri čemu uporaba sadrži primjenu terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kroz razdoblje odabrano od barem oko 3 mjeseca, barem oko 6 mjeseci, barem oko 1 godine, barem oko 2 godine i barem oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1 to improve in a subject in need thereof a biochemical marker of a LSD over time, wherein the use comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1 kako bi se kod pacijenta kojemu je to potrebno poboljšao biokemijski marker LSD-a tijekom vremena, pri čemu uporaba sadrži primjenu terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kroz razdoblje odabrano od barem oko 3 mjeseca, barem oko 6 mjeseci, barem oko 1 godine, barem oko 2 godine i barem oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-8, wherein the use comprises initiating administration of a therapeutically effective amount of acetyl-leucine to the subject in need thereof when the subject is asymptomatic. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-8, pri čemu uporaba sadrži iniciranje primjene terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kada je subjekt bez simptoma.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to claim 9, wherein the initial administration occurs after the subject has been found to have a genetic and/or biochemical marker of the LSD. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 9, pri čemu se prvotna primjena odvija nakon što je za subjekta ustanovljeno da ima genetski i/ili biokemijski marker LSD-a.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-5, wherein the method comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-5, pri čemu postupak sadrži primjenu terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kroz razdoblje odabrano od barem 3 oko mjeseca, barem oko 6 mjeseci, barem oko 1 godine, barem oko 2 godine i barem oko 5 godina.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-11, wherein the method comprises administering the acetyl-leucine to the subject in need thereof at a therapeutically effect amount of from about 1 g to about 15 g per day, from about 1 g to about 10 g per day, from about 1.5 g to about 7 g per day, from about 4 g to about 6 g per day, or from about 4 g to about 5 g per day. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-11, pri čemu postupak sadrži primjenu acetil-leucina na subjektu kojemu je to potrebno u terapeutski djelotvornoj količini od oko 1 g do oko 15 g dnevno, od oko 1 g do oko 10 g dnevno, od oko 1,5 g do oko 7 g dnevno, od oko 4 g do oko 6 g dnevno, ili od oko 4 g do oko 5 g dnevno.
An antibody composition for use in preventing or treating an infection with a HBV having a G145R mutation of HBV surface antigen (HBsAg) or a YMDD (tyrosine-methionine-aspartate-aspartate) mutation of HBV DNA polymerase, the composition comprising, as an active ingredient, an antibody comprising: a heavy-chain variable region (VH) having the amino acid sequence of SEQ ID NO: 2, and a light-chain variable region (VL) having the amino acid sequence of SEQ ID NO: 7. 
Pripravak protutijela namijenjen upotrebi u sprječavanju ili liječenju infekcije HBV-om s mutacijom G145R površinskog antigena HBV-a (HBsAg) ili mutacijom YMDD (tirozin-metionin-aspartat-aspartat) HBV DNA-polimeraze, naznačen time što pripravak sadrži, kao aktivni sastojak, protutijelo koje sadrži: varijabilno područje teškog lanca (VH) s aminokiselinskim slijedom SEQ ID NO: 2 i varijabilno područje lakog lanca (VL) s aminokiselinskim slijedom SEQ ID NO: 7.
The antibody composition for the use of claim 2, wherein the antiviral agent comprises one or more selected from the group consisting of interferon, anti-HBV monoclonal antibodies, anti-HBV polyclonal antibodies, nucleoside analogues, DNA polymerase inhibitors, and siRNA preparations. 
Pripravak protutijela namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što protuvirusno sredstvo sadrži jedno ili više od onoga što se bira iz skupine koju čine interferon, monoklonska protutijela protiv HBV-a, poliklonska protutijela protiv HBV-a, nukleozidni analozi, inhibitori DNA-polimeraze, te pripravci siRNA.
The antibody composition for the use of any one of claims 1 to 4, wherein the virus is mutant hepatitis B virus (HBV) resistant to lamivudine, adefovir dipivoxil, or HBIG (hepatitis B immunoglobulin). 
Pripravak protutijela namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je virus mutantni virus hepatitisa B (HBV), otporan na lamivudin, adefovir dipivoksil ili HBIG (imunoglobulin protiv hepatitisa B).
A pharmaceutical formulation for use in preventing or treating an infection with a HBV having a G145R mutation of HBV surface antigen (HBsAg) or a YMDD (tyrosine-methionine-aspartate-aspartate) mutation of HBV DNA polymerase, containing the antibody composition of any one of claims 1 to 6 as an active ingredient. 
Farmaceutska formulacija namijenjena upotrebi u sprječavanju ili liječenju infekcije HBV-om s mutacijom G145R površinskog antigena HBV-a (HBsAg) ili mutacijom YMDD (tirozin-metionin-aspartat-aspartat) HBV DNA-polimeraze, naznačena time što sadrži pripravak protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 6 kao aktivni sastojak.
The pharmaceutical formulation for the use of claim 7, further comprising one or more selected from the group consisting of carriers, excipients, and diluents. 
Farmaceutska formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 7, naznačena time što dodatno sadrži jedno ili više od onoga što se bira iz skupine koju čine nosači, pomoćne tvari i razrjeđivači.
The pharmaceutical formulation for the use of claim 7 or 8, wherein the formulation is in the form selected from the group consisting of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, and sterile packaged powder. 
Farmaceutska formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 7 ili 8, naznačena time što je formulacija u obliku kojeg se bira iz skupine koju čine tableta, pilula, prašak, vrećica, ljekoviti napitak, suspenzija, emulzija, otopina, sirup, aerosol, meka i tvrda želatinska kapsula, sterilna injekcijska otopina, te sterilno pakirani prašak.
The pharmaceutical formulation for the use of any one of claims 7 to 9, wherein the pharmaceutical formulation is administered to mammals at a dose of 0.001-10 mg/kg. 
Farmaceutska formulacija namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 7 do 9, naznačena time što se farmaceutsku formulaciju primjenjuje na sisavcima u dozi od 0,001-10 mg/kg.
The peptide as claimed in claim 1, formulated for enteral administration. 
Peptid, sukladno patentnom zahtjevu 1 ili 2, formuliran za enteralnu primjenu.
The peptide as claimed in claim 1, formulated for parenteral administration. 
Peptid, sukladno patentnom zahtjevu 1 ili 2, formuliran za parenteralnu primjenu.
The peptide as claimed in claim 4, formulated for injection. 
Peptid, sukladno patentnom zahtjevu 4, formuliran kao injekcija.
The peptide of claim 1, wherein the peptide is amidated at its C-terminal. A pharmaceutical composition comprising the peptide of claim 1 coated with citric acid particles wherein the coated citric acid particles increase the oral bioavailability of the peptide. 
Peptid sukladno patentnim zahtjevima 1 do 3, 6 ili 7, naznačen time, što je peptid formuliran kao farmaceutski spoj za oralnu primjenu koja sadrži čestice obložene limunskom kiselinom, i gdje obložene čestice limunske kiseline povećavaju oralnu biodostupnost peptida.